 Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 TLR4 Blinded interim analysis from Phase 23 study expected in current quarter TORONTO, ON ACCESSWIRE August 26, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on a Phase 23 clinical study evaluating the companys monoclonal antibody candidate as a single-dose therapy for hospitalized COVID-19 patients. As of August 25, 2021, Edesa reported that more than 525 subjects have been randomized into the study to be treated with either Edesas monoclonal antibody designated EB05 plus standard of care treatment, or placebo plus standard of care. 